COMMUNIQUÉS West-GlobeNewswire

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
27/03/2025
Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE [...]
Precision Optics to Participate in the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025
27/03/2025
GARDNER, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries [...]
Tempest Reports Year End 2024 Financial Results and Provides Business Update
27/03/2025
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat [...]
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
27/03/2025
Company to Host Conference Call Today, March 27, at 4:30pm ET BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company [...]
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
27/03/2025
Webcast Scheduled for Thursday, April 3 at 4:30 p.m. Eastern CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and [...]
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
27/03/2025
Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced [...]
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
27/03/2025
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated [...]
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
27/03/2025
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for [...]
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update
27/03/2025
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Accolade Stockholders Approve Merger Between Accolade and Transcarent
27/03/2025
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting [...]
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
27/03/2025
Webcast Today at 4:30 pm Eastern Time DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically [...]
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
27/03/2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated [...]
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
27/03/2025
MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
27/03/2025
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS ® (XIPERE ® ) for Uveitic Macular Edema Accepted for [...]
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
27/03/2025
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a [...]
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
27/03/2025
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette [...]
AEON Biopharma Announces CEO Transition
27/03/2025
– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 [...]
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
27/03/2025
The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™ HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage [...]
Better Choice Company Announces Fourth Quarter and Full Year 2024 Financial Results
27/03/2025
Fourth Quarter 2024 Revenue Growth of 26% Year-Over-Year to $7.2 million Fourth Quarter 2024 Loss per Share Improves 97% Year-Over-Year to $(0.50) Fourth Quarter 2024 Adjusted EBITDA Loss Improves 80% to $(0.7) million [...]

Pages